Beta-Lactam

Phase 3Small molecule

Roche

Beta-Lactam is one of 3 small molecule programs targeting Bacteremia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BacteremiaRecruiting

BacteremiaPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Bacteremia

#DrugCompanyPhaseTrials

Pradaxa

Boehringer Ingelheim

Approved

1 2

Beta-Lactam

Roche

Phase 3

1 3

Ceftolozane/tazobactam

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedRecruiting

Bacteremia

NCT07240077

Clinical

Trials by Indication[1]

Bacterial Pneumonia1 trial

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

Completed· Roche logo

Roche·Phase 2·NCT00111644·302 enrolled

Staphylococcus aureus infection1 trial

Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection

Terminated·MMenzies School of Health Research·Phase 3·NCT02365493·358 enrolled

Hospitalized Patients1 trial

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

Completed· Roche logo

Roche·Phase 2·NCT00303589·313 enrolled

Bacteremia1 trial

Beta-lactam Monotherapy Versus Beta-lactam Plus Levofloxacin for the Treatment of Streptococcal Bacteremia: A Multicenter, Randomized, Double-Blind, Pragmatic Trial

Recruiting·MMahidol University·Approved·NCT07240077·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Beta-Lactam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Beta-Lactam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Beta-Lactam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Beta-Lactam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Bacterial Pneumonia1 trial

Staphylococcus aureus infection1 trial

Hospitalized Patients1 trial

Bacteremia1 trial

References

Drug Info

Quick Facts

Related News